Acetyl-L-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection

HIV Medicine

Volumn 10, Issue 2, 2009, Pages 103-110

  Valcour, Victor ^a,b   Yeh, T M ^c   Bartt, R ^d   Clifford, D ^e   Gerschenson, M ^a   Evans, S R ^c   Cohen, B A ^f   Ebenezer, G J ^g   Hauer, P ^g   Millar, L ^h   Gould, M ^e   Tran, P ⁱ   Shikuma, C ^a   Souza, S ^a   Mcarthur, J C ^g  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Fat; HIV; Mitochondria; Neuropathy

Indexed keywords

LEVACECARNINE; MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIRETROVIRAL TOXIC NEUROPATHY; ARTICLE; BODY FAT; CELL DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG TOLERABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LEG; MITOCHONDRIAL TOXICITY; NERVE FIBER; NEUROLOGIC EXAMINATION; NEUROPATHY; OPEN STUDY; PAIN ASSESSMENT; PARESTHESIA; PILOT STUDY; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; SKIN BIOPSY; SYMPTOMATOLOGY; THIGH; TREATMENT DURATION; TREATMENT RESPONSE;

ACETYLCARNITINE; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CONFIDENCE INTERVALS; DNA, MITOCHONDRIAL; FEMALE; HIV-1; HUMANS; MALE; MIDDLE AGED; NERVE FIBERS; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PILOT PROJECTS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 68949135775     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00658.x     Document Type: Article

References (27)

1. Verma S, Estanislao L, Simpson D. HIV-associated neuropathic pain: epidemiology, pathophysiology and management. CNS Drugs 2005; 19: 325-334.
2. So YT, Holtzman DM, Abrams DI, Olney RK. Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. Arch Neurol 1988; 45: 945-948.
3. Marra CM, Boutin P, Collier AC. Screening for distal sensory peripheral neuropathy in HIV-infected persons in research and clinical settings. Neurology 1998; 51: 1678-1681.
4. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: Risk factors, incidence and management. Drug Saf 1998; 19: 481-494.
5. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005; 4: 543-555.
6. Blum AS, Dal Pan GJ, Feinberg J et al. Low-dose zalcitabine-related toxic neuropathy: Frequency, natural history, and risk factors. Neurology 1996; 46: 999-1003.
7. Schifitto G, McDermott MP, McArthur JC et al. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002; 58: 1764-1768.
8. Chen CH, Vazquez-Padua M, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991; 39: 625-628.
9. Brew BJ, Tisch S, Law M. Lactate concentrations distinguish between nucleoside neuropathy and HIV neuropathy. AIDS 2003; 17: 1094-1096.
10. Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS 1999; 13: 2311-2312.
11. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000; 22: 911-936; discussion 898.
12. Famularo G, Moretti S, Marcellini S et al. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS 1997; 11: 185-190.
13. Simpson DM, Katzenstein D, Haidich B et al. Plasma carnitine in HIV-associated neuropathy. AIDS 2001; 15: 2207-2208.
14. De Simone C, Famularo G, Tzantzoglou S, Trinchieri V, Moretti S, Sorice F. Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS: Effect of oral l - carnitine. AIDS 1994; 8: 655-660.
15. Hart AM, Wilson AD, Montovani C et al. Acetyl-l-carnitine: A pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS 2004; 18: 1549-1560.
16. Youle M. Acetyl-l-carnitine in HIV-associated antiretroviral toxic neuropathy. CNS Drugs 2007; 21 (Suppl. 1): 25-30, 45-6.
17. McArthur JC, Stocks EA, Hauer P, Cornblath DR, Griffin JW. Epidermal nerve fiber density: Normative reference range and diagnostic efficiency. Arch Neurol 1998; 55: 1513-1520.
18. Stocks EA, McArthur JC, Griffen JW, Mouton PR. An unbiased method for estimation of total epidermal nerve fibre length. J Neurocytol 1996; 25: 637-644.
19. Ebenezer GJ, Hauer P, Gibbons C, McArthur JC, Polydefkis M. Assessment of epidermal nerve fibers: A new diagnostic and predictive tool for peripheral neuropathies. J Neuropathol Exp Neurol 2007; 66: 1059-1073.
20. Kennedy W, Wendelschafer-Crabb G, Polydefkis M, McArthur J. Pathology and quantitation of cutaneous innervation, In: Dyck P, Thomas P. eds. Peripheral Neuropathies. Philadelphia: Saunders, 2005, pp. 869-895.
21. Lauria G, Cornblath DR, Johansson O et al. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol 2005; 12: 747-758.
22. Gerschenson M, Shiramizu B, LiButti DE, Shikuma CM. Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals. Antivir Ther 2005; 10 (Suppl. 2): M83-M89.
23. Simpson DM, Kitch D, Evans SR et al. HIV neuropathy natural history cohort study: Assessment measures and risk factors. Neurology 2006; 66: 1679-1687.
24. Youle M, Osio M. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl l-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med 2007; 8: 241-250.
25. Alesci S, Gerschenson M. l-carnitine and human immunodeficiency virus-related disorders. Chem Mon 2005; 136: 1493-1500.
26. Kitayama H, Miura Y, Ando Y, Hoshino S, Ishizaka Y, Koyanagi Y. Human immunodeficiency virus type 1 Vpr inhibits axonal outgrowth through induction of mitochondrial dysfunction. J Virol 2008; 82: 2528-2542.
27. Robinson B, Li Z, Nath A. Nucleoside reverse transcriptase inhibitors and human immunodeficiency virus proteins cause axonal injury in human dorsal root ganglia cultures. J Neurovirol 2007; 13: 160-167.